Patent ID: 11965894
Assignee: ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
Field: Measurement (Instruments)
Classification: CPC G | IPC G

Claim 0:
1. A method for assessing and treating Drug-Induced-Liver-Injury (DILI) in a patient receiving a drug comprising:
(a) measuring markers present in a blood, serum, or plasma sample from the patient to determine concentrations for the markers, wherein the markers are selected from of ApoA1 (Apolipoprotein A-I), A2M (a2-macroglobulin), GGT (gammaglutamyl transpeptidase), and Haptoglobin;
(b) assigning a value of 0 if the patient is female or assigning a value of 1 if the patient is male;
(c) obtaining the patient's age;
(d) combining the concentrations of (a), the value of (b), and the age of (c) through a logistic regression function and obtaining an end-result value,
wherein
the logistic regression function is 0.605+0.027×Age (years)+1.197×ApoA1 (g/L)−1.31×LogA2m (g/L)−1.011×LogGGT (IU/L)+0.24×LogHaptoC (g/L)−0.44×Sex (0 for women, 1 for men);

(e) assessing the end-result value to identify a patient at risk for developing acute liver failure, wherein the patient is at risk for developing acute liver failure when the end-result value is above 0.75; and
(f) treating the patient at risk for developing acute liver failure by stopping the patient at risk for developing acute liver failure from receiving the drug.